Orally administered Giardia duodenalis extracts enhance an antigen-specific antibody response

Dunn, Linda A., Upcroft, Jacqueline A., Fowler, Elizabeth V., Matthews, Ben S. and Upcroft, Peter (2001) Orally administered Giardia duodenalis extracts enhance an antigen-specific antibody response. Infection And Immunity, 69 10: 6503-6510. doi:10.1128/IAI.69.10.6503-6510.2001

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ60846_OA.pdf Full text (open access) application/pdf 560.52KB 0

Author Dunn, Linda A.
Upcroft, Jacqueline A.
Fowler, Elizabeth V.
Matthews, Ben S.
Upcroft, Peter
Title Orally administered Giardia duodenalis extracts enhance an antigen-specific antibody response
Journal name Infection And Immunity
ISSN 1098-5522
Publication date 2001-10
Sub-type Article (original research)
DOI 10.1128/IAI.69.10.6503-6510.2001
Open Access Status File (Publisher version)
Volume 69
Issue 10
Start page 6503
End page 6510
Total pages 8
Place of publication Washington, DC, United States
Publisher American Society of Microbiology
Collection year 2001
Language eng
Abstract We have identified novel adjuvant activity in specific cytosol fractions from trophozoites of Giardia isolate BRIS/95/HEPU/2041 (J. A. Upcroft, P. A. McDonnell, and P. Upcroft, Parasitol. Today, 14:281-284, 1998). Adjuvant activity was demonstrated in the systemic and mucosal compartments when Giardia extract was coadministered orally with antigen to mice. Enhanced antigen-specific serum antibody responses were demonstrated by enzyme-linked immunosorbent. assay to be comparable to those generated by the gold standard, mucosal adjuvant cholera toxin. A source of adjuvant activity was localized to the cytosolic component of the parasite. Fractionation of the cytosol produced fraction pools, some of which, when coadministered with antigen, stimulated an enhanced antigen-specific serum response. The toxic component of conventional mucosal adjuvants is associated with adjuvant activity; therefore, in a similar way, the toxin-like attributes of BRIS/95/HEPU/2041 may be responsible for its adjuvanticity. Complete characterization of the adjuvant is under way.
Keyword Immunology
Infectious Diseases
Mucosal Immunity
Vaccine Development
Neonatal Mice
Q-Index Code C1
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 9 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 14 Aug 2007, 16:49:20 EST